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ARTICLE
Red-Green Color Vision Impairment in Duchenne Muscular
Dystrophy
Marcelo Fernandes Costa, Andre Gustavo Fernandes Oliveira, Claudia Feitosa-Santana,
Mayana Zatz, and Dora Fix Ventura
The present study evaluated the color vision of 44 patients with Duchenne muscular dystrophy (DMD) (mean age 14.8
years; SD 4.9) who were submitted to a battery of four different color tests: Cambridge Colour Test (CCT), Neitz An-
omaloscope, Ishihara, and American Optical Hardy-Rand-Rittler (AO H-R-R). Patients were divided into two groups
according to the region of deletion in the dystrophin gene: upstream of exon 30 ( ) and downstream of exon 30np 12
( ). The control group was composed of 70 age-matched healthy male subjects with no ophthalmological com-np 32
plaints. Of the patients with DMD, 47% (21/44) had a red-green color vision defect in the CCT, conﬁrmed by the Neitz
Anomaloscope with statistical agreement ( ). The Ishihara and the AO H-R-R had a lower capacity to detect colorP ! .001
defects—5% and 7%, respectively, with no statistical similarity between the results of these two tests nor between CCT
and Anomaloscope results ( ). Of the patients with deletion downstream of exon 30, 66% had a red-green colorP 1 .05
defect. No color defect was found in the patients with deletion upstream of exon 30. A negative correlation between
the color thresholds and age was found for the controls and patients with DMD, suggesting a nonprogressive color defect.
The percentage (66%) of patients with a red-green defect was signiﬁcantly higher than the expected !10% for the normal
male population ( ). In contrast, patients with DMD with deletion upstream of exon 30 had normal color vision.P ! .001
This color defect might be partially explained by a retina impairment related to dystrophin isoform Dp260.
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Duchenne muscular dystrophy (DMD [MIM 310200]),
which affects 1:3,500 newborn males,1–3 is the most com-
mon form of progressive muscular dystrophy disease. It is
caused by a deﬁciency in the protein called “dystrophin.”4
The dystrophin gene, at Xp21, has 79 exons.2 DMD is
caused by deletions in the dystrophin gene in 60%–65%
of patients, by duplications in 5%–10%, and by pointmu-
tations or small rearrangements in the remaining 20%–
30%. The main pathological effects caused by mutations
in the dystrophin gene are in the skeletal and cardiacmus-
cles, although dystrophin is present in several other tissues
of the body, including a widespread distribution in the
nervous system.5
In addition to full-length dystrophin, four other shorter
proteins are transcribed from the DMD gene: Dp260 (tran-
scripts spliced to exon 30), Dp140 (transcripts spliced to
exon 44), Dp116 (transcripts spliced to exon 56), and
Dp71 (transcripts spliced to exon 63).6,7
In the retina, dystrophin is expressed at the level of the
outer plexiform layer (Dp260) in the inner limiting mem-
brane (Dp71).7–12 Dp260 is also found at the cone pedicle,
in the region of the ribbon synapse.13 Electrophysiological
studies showed that Dp260 is essential for the physiology
of the retina, since patients with DMD and deletions
downstream of exon 30 had serious impairment in both
scotopic and photopic responses obtained by full-ﬁeld
electroretinogram (ERG).6,14–24 The role of Dp71 in the ret-
inal electrophysiology is still unknown. In the work of
Claudepierre et al.,8 it was associated with the b-waveMul-
ler cells’ contribution to the ERG. Dp427 and Dp140 are
also present in mouse retina but do not appear to make
an important contribution to the ERG.25
Previous studies of color vision in patients with DMD
or Becker muscular dystrophy (BMD), based on Ishihara
and American Optical Hardy-Rand-Rittler (AO H-R-R)
tests, found that the proportion of red-green defect in this
group26,27 was in accordance with the proportion observed
for the normal population. However, the Ishihara and AO
H-R-R tests are screening tests used to detect severe red-
green deﬁciency,28,29 but they are not sufﬁciently sensitive
to detect moderate or light impairment. Recent studies
have demonstrated an advantage of computerized color
vision tests over the semiquantitative tests classically used
in the evaluation of color vision, such as the Farnsworth-
Munsell 100-Hue Test. The advantage is due to several
aspects inherent to the programmed presentation of test-
ing trials and to the advances in computerized color re-
production, since (1) rigorous psychophysical methodol-
ogy is used, (2) changes in the chromatic steps can be
varied according to the subject being tested, (3) the res-
olution of the chromatic steps is sufﬁciently ﬁne to allow
threshold measurement, and (4) online computation of
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the results is available. A shortcoming of the computerized
tests is that they are new and experimental, and most are
not commercially available. An exception to this limita-
tion is a test designed by Mollon and Refﬁn,30 which is
available commercially as the Cambridge Colour Test
(CCT).
In the present study, we therefore reexamined color vi-
sion in patients with DMD, using this new color vision
test, which is much more detailed and has been rated as
more sensitive than the traditional tests.31–35 Because it is
programmed to simultaneously test the three cone-isola-
tion axes, the CCT allows a more reﬁned analysis of the
visual pathways involved in chromatic processing—the
parvocellular pathway, which mediates red-green color
vision, and the koniocellular pathway, which mediates
yellow-blue color vision.31,32,34,35 We also used the Ano-
maloscope test—a gold standard for the detection of red-
green defect—and, in addition, the Ishihara and AO H-R-
R tests, which had been used in the early studies of
patients with DMD.
Methods
Subjects
We evaluated 50 patients with DMD ranging in age from 9 to 21
years (mean 14.9 years; SD 4.3) who were referred by the Asso-
ciac¸a˜o Brasileira de Distroﬁa Muscular (ABDIM) and had been
given diagnoses and been followed up by the Human Genome
Research Center of the Institute of Biosciences of the University
of Sa˜o Paulo. This study followed the tenets of the Declaration
of Helsinki. Informed consent was obtained from the subjects
after the nature of the study was explained.
The diagnosis of DMD was established by clinical and neuro-
logical examination, family history, grossly elevated serum cre-
atinine levels, and DNA analysis. It is known that ∼60%–65% of
patients with DMD have deletions in the dystrophin gene. De-
letion screening used a set of 18 primers that allowed detection
of 98% of the deleted exons and that were developed by Cham-
berlain36 and Beggs.37 Motor performance of the patients with
DMD was assessed and classiﬁed according the Vignos Scale, a
scale of motor-function evaluation speciﬁc to neuromuscular dis-
eases.38 The assessment was made by physiotherapists from the
ABDIM staff. A total of 50 patients with known deletions in the
dystrophin gene were selected for this study. They were classiﬁed
into two groups according to the deleted region: patients with
deletions upstream of exon 30 ( ) and patients with dele-np 12
tions downstream of exon 30 ( ). This distinctionwasmadenp 38
because retinal dystrophin, Dp260, is known to splice in at exon
30. The demographic data of the 50 patients withDMDare shown
in table 1.
An ophthalmological examination was performed for all sub-
jects, to eliminate confounding pathologies, such as cataracts,
retinopathy, or neuropathy. Fundoscopy was performed with in-
direct ophthalmoscopy. Visual acuity was measured at 3 m with
use of an ETDRS chart (tumbling E). All patients had normal eye
fundus and 20/20 or better best-corrected visual acuity. To con-
stitute the control group, 75 healthy male subjects ranging in age
from 9 to 22 years (mean 13.9 years; SD 4.3) were tested. Inclusion
criteria for this group were normal eye fundus, 20/20 or better
best-corrected visual acuity, and absence of color vision defects.
Five (7%) male subjects did not meet the criteria, since they had
congenital color vision defect, and were excluded from the anal-
ysis. With these exclusions, the control group was composed of
70 subjects ranging in age from 9 to 22 years (mean 14.6 years;
SD 4.9).
Equipment and Procedures
The evaluation of the color discrimination was performed using
the commercial version of CCT (v2.0 [Cambridge Research In-
struments]) installed in a personal computer (Dell Dimension
XTC-600) with a graphic board VSG 2/5 (Cambridge Research
Instruments). The stimuli were generated in a high-resolution
color monitor, Sony FD Trinitron model GDM-F500T9 (Sony).
Testing was conducted in a dark room with the patients posi-
tioned 3 m away from the monitor.
The stimulus provided by the CCT was similar to those used
in the pseudoisochromatic plate tests, such as the Ishihara test
(Kanehara & Co.) or the AO H-R-R (Richmond Products). The
target consisted of a Landolt “C” that differed in chromaticity
from the single neutral background (coordinates 0.1977, 0.4689
of of the International Commission on Illumination [CIE]′′u v
1976 color space) (ﬁg. 1). The Landolt C gap size corresponded
to 1.25 of visual angle, with the outer diameter 5.4 and the
inner diameter 2.75 at the test distance of 3 m. Both target and
background were composed of small patches of varying sizes (0.5–
2 cm in diameter) and six luminance levels (8, 10, 12, 14, 16,
and 18 candela [cd]#m2) randomly distributed in the display.
This design used spatial and luminance noise to avoid the inﬂu-
ence of cues derived from luminance differences or from target
contours in the intended hue discrimination.
The target was randomly presented with its opening in one of
four positions: up, bottom, right, and left (4-Alternative Forced
Choice strategy). The patient’s task was to press one of the four
buttons of the response box (CT3 [Cambridge Research Instru-
ments]), to indicate the position of the “C” opening. The patients
had up to 15 s to give the response. Patients with motor im-
pairment verbally indicated the gap position, and the examiner
pressed the buttons.
A psychophysical staircase procedure was used for threshold
determination. Each staircase began with a saturated chromatic-
ity, which was changed along the vector connecting it to the
background chromaticity. The change depended on the patient’s
response: the target chromaticity approached the background
chromaticity every time there was a correct response and moved
away from it every time there was an incorrect response or no
response. The chromaticity excursion along the vectors ranged
from 0.1100 to 0.0020 units of CIE 1976 . After six staircase′′u v
reversals, the program automatically calculated the threshold for
that vector as the average of the chromaticities corresponding to
the reversals. The step size used in the staircase followed a dy-
namic rule (for more details on the CCT methodology, see the
work of Regan et al.,39 and, for CCT norms, see the work of Ven-
tura et al.32).
The CCT has two testing procedures. The Trivector test is used
to determine thresholds along the protan, deutan, and tritan con-
fusion lines (ﬁg. 1). In this procedure, the three corresponding
staircases are conducted simultaneously, in an interleaved way,
changing randomly from one to the other. Periodically, a control
target at maximum saturation is presented, as a catch trial.
The other CCT procedure is used for the construction of a dis-
crimination ellipse (MacAdam ellipse). In this study, we used
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Table 1. Demographic Data and Color Test Results for the Patients with DMD
Patient Age
Deletion
in Exon
CCT Trivector CCT Ellipses
T/P T/D Neitz Ishihara H-R-R VignosProtan Deutan Tritan Area Angle
1 21 8 56 69 109 437.2 75.0 1.9 1.6 N N N …
2 20 7 49 62 88 608.4 60.3 1.8 1.4 N N N 9
3 10 5–13 97 98 130 793.7 178.7 1.3 1.3 N N N 8
4 17 8–27 39 35 58 169.8 67.6 1.5 1.7 … … … 8
5 17 8–9 46 46 75 569.7 72.6 1.6 1.6 … N N 9
6 23 3–7 176 470 64 10,000.0 159.6 .4 .1 D D D 7
7 10 11–15 69 54 97 587.1 70.1 1.4 1.8 N N N 6
8 15 8–12 58 62 59 509.8 68.3 1.02 .95 N N N 6
9 18 19 48 56 92 336.2 50.2 1.92 1.64 N N N 7
10 9 8–13 137 144 141 1,279.4 61.4 1.03 .98 N N N 4
11 11 8–13 119 102 113 765.8 41.3 .95 1.11 N N N 6
12 10 8–13 86 56 127 626.9 53.0 1.5 2.3 N N N 7
13 9 47–52 99 105 209 4,441.1 23.0 2.1 2.0 P N N 7
14 9 48–52 141 134 118 1,251.5 46.8 .8 .9 … N RG 7
15 15 50 88 89 110 881.2 52.1 1.3 1.2 N N N …
16 15 47–48 69 79 117 708.8 57.7 1.7 1.5 … N N 9
17 12 50 81 64 81 478.5 105.5 1.0 1.3 N N N 9
18 20 40–42 … … … … … … … … … … 7
19 12 50 156 174 149 1,498.9 145.7 1.0 .9 … N N 9
20 13 47–50 117 120 205 3,365.9 81.6 1.8 1.7 … N N 7
21 8 50 119 107 82 1,264.7 67.3 .7 .8 N N N 7
22 9 45 102 74 122 955.1 62.9 1.2 1.6 P N N 7
23 16 49–50 72 89 80 528.0 28.6 1.1 .9 P N N 9
24 11 38–42 … … … … … … … … … … 7
25 9 43 281 195 144 2,827.0 164.2 .5 .7 D RG RG 7
26 9 47–52 139 46 103 747.2 59.6 .7 2.2 P N N 8
27 18 46–55 36 35 53 257.5 50.6 1.5 1.5 … N N 7
28 13 51 87 91 136 627.5 52.1 1.6 1.5 N N N …
29 21 49–52 146 188 249 1,563.3 78.4 1.7 1.3 P N N 7
30 20 45–47 42 40 26 502.7 95.0 .6 .7 … N N …
31 15 50 … … … … … … … … … … 9
32 20 51–52 46 69 69 578.5 89.6 1.5 1.0 N N N 9
33 18 48–51 84 84 129 739.0 85.5 1.5 1.5 … N N 9
34 9 … … … … … … … … … … 3
35 19 50 51 63 81 711.0 65.7 1.6 1.3 N N N 7
36 13 48–52 26 52 82 647.5 119.1 3.2 1.6 N N N 8
37 14 43–45 81 70 132 629.2 46.0 1.6 1.9 N N N 9
38 14 51 39 33 67 384.1 75.7 1.7 2.0 N N N 6
39 13 47 64 60 89 405.8 88.3 1.4 1.5 N N N 9
40 13 48–50 82 79 84 711.0 69.7 1.0 1.1 N N N 7
41 10 47–52 164 125 167 1,708.0 66.9 1.0 1.3 P N N 7
42 12 3–60 111 81 170 7,795.1 69.1 1.5 2.1 P N N 8
43 16 36 … … … … … … … … … … 8
44 16 43 122 73 154 1,432.8 53.5 1.3 2.1 … N N 7
45 10 45 79 85 107 830.3 84.8 1.4 1.3 N N N 1
46 8 46–55 … … … … … … … … … … 3
47 24 50–52 83 81 79 683.4 37.7 1.0 1.0 P N N 9
48 10 45–52 163 247 130 3,315.9 158.7 .8 .5 D N D 1
49 16 45–52 43 42 61 650.3 80.9 1.4 1.5 N N N 9
50 9 45–52 127 98 142 957.2 94.1 1.1 1.4 N N N 6
NOTE.—N p normal; D p deutan defect; P p protan defect; RG p red-green defect.
eight vectors spaced 45 apart to determine the discrimination
ellipse around the same background chromaticity that had been
used for the Trivector test. The staircases corresponding to these
vectors were run in interleaved pairs, randomly chosen by the
software. After the detection of the threshold in each vector, the
ellipse was traced by interpolation, with use of the minimum
squares method.
Inside the boundaries of the MacAdam ellipses, color discrim-
ination is lost. This means that, the smaller the ellipse, the better
the patient’s discrimination ability. The quantitative parameters
that are used to describe this ability are the ellipse length, the
axis ratio, and the ellipse angle in color space. Ellipse length and
angle are indicative of magnitude and type of color defect. We
used ellipse area to quantify these changes, as an indicator of the
patient’s performance in color discrimination.
To conﬁrm the type of red-green defect, the patients were also
tested with the type I Neitz Anomaloscope (model OT-II [Neitz
Instruments]), a standard test for the detection of red-green color
defects.40 The Neitz Anomaloscope determines the Rayleigh equa-
tion for the patient: the mixture of red (670 nm) and green (545
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Figure 1. Left, Image of the stimulus provided by the CCT, showing the spatial and luminance noise (small patches of different
diameters and luminances) and the letter “C” formed by the same patches at a chromaticity that differs from the background. Right,
CIE chromaticity diagram (1976 u′v′) used by the CCT. The gray area indicates all colors seen by the human visual system, and the color
triangle exhibits the chromaticities that can be displayed by the video monitor at the luminance level used in the tests. The lines P,
D, and T correspond to the protan, deutan, and tritan, respectively, confusion lines tested in the Trivector protocol.
nm) light that matches a reference yellow (589 nm) light.41 All
three lights are produced by ﬁlters of equal luminance. The ex-
perimental procedure consisted of the observation of a circular
horizontally bipartite ﬁeld with 2 of visual angle. The yellow
stimulus is in the lower hemiﬁeld, which can vary in luminance
from dark to bright yellow. The task of the patient is to adjust
the color of the upper hemiﬁeld to match the color and lumi-
nance of that presented at the lower hemiﬁeld. This is done by
adjusting the proportion of the mixture of the green (545 nm)
and red (670 nm) lights, whose combination is projected in the
upper ﬁeld. When both ﬁelds are matched in chromaticity, the
luminance of the ﬁeld is about 5 cd#m2. The proportion used
by trichromatic subjects with normal color vision is known from
normative studies and was determined here for the control group.
The exam was performed in a dark room, in accordance with the
procedure recommended by the 1981 National Research Council
Committee on Vision.40
The two pseudoisochromatic color plate tests, used in the ge-
netic studies reported elsewhere,26,27 were also used for the eval-
uation of color vision defects: Ishihara Test for Color Blindness
(24 plates edition [Kanehara & Co.]) and AO H-R-R Pseudoiso-
chromatic Plates (AO H-R-R [Richmond Products]). These tests
consist of a series of printed plates with spatial and luminance
noise forming a multicolored ﬁgure, which is also observed
against a multicolored background. The only systematic differ-
ence between the ﬁgure and the background is the color. Patients
with normal vision can detect the color differences betweenﬁgure
and the background, whereas patients with color defects fail to
do it. The AO H-R-R test was built for the detection, classiﬁcation,
and quantiﬁcation of red-green and blue-yellow defects. This test
is made up of 24 boards in which colored circles of several sizes
and luminances form ﬁgures in a background of gray circles also
of several sizes and luminances. These ﬁgures are a cross, a circle,
and a triangle. In the Ishihara test, there are numbers instead of
ﬁgures. The patients were asked to read the numbers in 6 s. This
response time was a slight adaptation made after consideration
of the characteristics of the study group. The Ishihara test detects
only protan and deutan defects and enables a more precise dif-
ferentiation between both kinds of defects.
Response Reliability
The CCT software incorporates a reliability-testing procedure
with catch trials, which present a saturated color at themaximum
of the cathode ray tube gamut. These catch trials are presented
at different times in the test session and constitute ∼10% of the
stimuli. For the Trivector, one color was used in the catch trial
(CIE 1976 coordinates: ; ; vector length 1,100′′u p .119 v p .391
units); for the ellipses, another chromaticity was used (CIE′′u v
1976 coordinates: ; ; vector length 1,100′ ′′ ′u p .308 v p .469 u v
units). These saturated colors are discriminated even by patients
with severe color vision impairment. This procedure tests the
ability of the subject to respond correctly to the target, which
depends on the understanding of instructions and on the atten-
tion directed to the task during the testing session. We deﬁne the
percentage of correct responses to these catch trials as a measure
of reliability. Reliability was 100% for both control subjects and
patients with DMD—that is, there were no mistakes in the catch
trials. This means that the subjects were performing the required
task correctly during the entire length of the testing session.
Statistical Analysis
Statistical analysis was performed with the software Statistica
(StatSoft v.6). Statistical differences among the groups were ver-
iﬁed with the x2 test, the Mann-Whitney U test, and the Kruskal-
Wallis analysis of variance (ANOVA) by ranks. We use the Tukey
honest signiﬁcance difference (HSD) design for unequal N, to
determine the signiﬁcant differences between groupmeans in the
ANOVA setting. The Wilcoxon test was used to assess differences
in the Ishihara and AO H-R-R categorical color vision classiﬁca-
tion. The Spearman rank test correlation was used to verify the
relationship between color vision results and the other vari-
ables—age and Vignos score. A cluster analysis was performed by
measuring a Euclidian distance in a complete linkage rule, to
verify similarities and dissimilarities among parameters of the
color vision tests, Vignos score, and gene deletion. Adhesion to
the normal distribution was checked with the Kolmogorov-Smir-
nov test.
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Figure 2. Color discrimination thresholds of the patients with
DMD and control subjects (meanSD) for the protan, deutan, and
tritan confusion lines of the Trivector test. Statistical difference
was signiﬁcant for all three confusion lines.
Table 2. Age versus Color Thresholds Product-Moment
Correlation Index
Study
Group
Protan Deutan Tritan
r P r P r P
Controls .568 !.001 .463 !.001 .479 !.001
DMD .390 .004 .266 NS .243 NS
Up 30a .758 .006 .281 .004 .606 .047
Down 30b .551 .002 .408 .020 .395 .025
NOTE.—NS p no statistical signiﬁcance.
a Gene deletion upstream of exon 30.
b Gene deletion downstream of exon 30.
Results
The battery of color tests could be performed in 88% (44/
50) of the patients with DMD. The remaining six patients
with DMDhad difﬁculty understanding or performing the
task in the CCT and were excluded from our analysis. The
Anomaloscope test was performed in 77% (34/44) of the
remaining patients with DMD. The color vision results are
shown in tables 1 and 2 (rightmost columns). One patient
with DMD (table 1, number 6) had a congenital dichro-
matic defect classiﬁed as deuteranopia and was excluded
from our statistical analysis.
Color discrimination results from subjects with DMD
and controls in the CCT Trivector (ﬁg. 2) showed signif-
icant differences in the Kruskal-Wallis ANOVA for all three
color confusion axes (protan , ; deutanHp 27.216 P ! .001
, ; tritan , ). In ad-Hp 30.232 P ! .001 Hp 19.005 P ! .001
dition,MacAdam ellipses areas obtainedwith theCCThad
larger areas in the patients with DMD compared with the
controls ( , ).Hp 27.302 P ! .001
For the CCT Trivector axes, we calculated the tritan/
protan (T/P) and tritan/deutan (T/D) ratios. For the con-
trols, the tritan thresholds are always higher compared
with the thresholds of the protan and deutan thresholds,
because of distortions of the CIE color space. Alterations
in these ratios compared with those of the controls might
be used as an indication of color vision anomaly, even if
each of the color discrimination thresholds are within the
normal tolerance limits. Furthermore, alterations in these
ratios are indicative of the type of anomaly. No alteration
occurs if the anomaly is diffuse—that is, if there is a uni-
form change in thresholds. Other patterns reveal speciﬁc
losses.
For controls, the mean value of the T/P ratio was 1.68
(SD 0.36), and that of the T/D ratio was 1.69 (SD 0.40).
For the patients with DMD, the T/P and T/D ratios of the
patients with normal thresholds in all Trivector axes, with
consideration of the tolerance limits calculated for the
control group, were considered. The mean T/P ratio was
1.40 (SD 0.40), and the mean T/D ratio was 1.43 (SD 0.44)
for patients with DMD. A statistically signiﬁcantdifference
was found between controls and patients with DMD for
the T/P (Mann-Whitney U test: , ) andUp 998.90 P ! .003
for T/D ( , ) ratios. This reduction ofUp 1,003.90 Pp .005
the T/P and T/D ratios indicates a red-green defect, since
it results from the fact that the mean thresholds for the
protan and deutan axes were elevated relative to themean
tritan threshold.
A red-green color defect was found in 47% (21/44) of
the patients with DMD in the CCT. These results were
conﬁrmed by the Rayleigh equation, obtained with the
Neitz Anomaloscope. A x2 test showed that there was no
difference between the classiﬁcations of the color vision
defect based on the CCT and on the Anomaloscope
( , ). Diffuse defects were found in 3/442x p 0.680 Pp .495
(7%) patients.
The Ishihara and AO H-R-R color vision tests detected
color vision alterations in fewer patients: the AO H-R-R
was able to identify only 3 of 44 (7%), and the Ishihara
2 of 44 (5%), of red-green color vision losses in patients
with DMD. In all these cases, a red-green color defect was
also detected by the CCT.
A categorical comparison (Wilcoxon test) of color de-
fects obtained with the Ishihara and with the CCT shows
that the two tests differ in the ability to detect color defects
( , ). The same comparison betweenWp26.000 Pp .026
the AO H-R-R test and the CCT also shows that the results
of the two tests differ even more signiﬁcantly (Wp
, ). The same analysis was made to compare95.000 P ! .001
the Ishihara and the AO H-R-R color vision classiﬁcation
with the Neitz Anomaloscope. It showed that these two
tests have a lower sensitivity to detect red-green color de-
fects than the Anomaloscope (Ishihara, ,Wp20.000
; AO H-R-R, , ).Pp .021 Wp94.000 Pp .009
Color vision thresholds of the control subjects decreased
with increasing age, from 9 to 21 years, conﬁrming an
improvement in discrimination capacity during this age
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period, as shown in the literature.42 This improvementwas
also observed in the patients with DMD. Spearman rank
order correlations between color thresholds and age were
negative and statistically signiﬁcant for the three CCT Tri-
vector thresholds and for the ellipses area (table 2).
To describe quantitatively the relationship between the
color vision result parameters and the genotype vari-
ables—region of the gene deletion—we performed a clus-
ter analysis, measuring Euclidian distance in a complete
linkage rule. Two clusters were found: one cluster was
formed by the area results of the CCT ellipses, and another
cluster linked the CCT results with the region of the ge-
netic deletion. In the latter, there are two segregations.
The ﬁrst shows proximity among the region of the gene
deleted with the T/P and T/D ratio. The second cluster
connects the CCT Trivector results and CCT ellipses angle.
Both clusters had an insigniﬁcant distance as compared
with the CCT ellipses area result.
Since the cluster analysis reveals that there is an asso-
ciation between the CCT color vision results and the re-
gion of gene deletion, we analyzed statistical signiﬁcances
considering this parameter. The criterion to separate the
DMD patients in groups was based on the ERG studies
that showed that exon 30 is essential for normal retina
electrophysiology.14,25,43
Figure 3 shows color vision deﬁciencies found in the
patients with DMD with known deletions, including the
patient with congenital color defect excluded previously.
In panel A, we see that all patients except one have de-
letions downstream of exon 30. Of 19 patients with nor-
mal color vision, 8 have deletions downstream of exon
30, and 11 have deletions upstream of exon 30. These data
are summarized in ﬁgure 3B.
Patients with DMD were therefore stratiﬁed into two
subgroups according to gene deletion: those with deletion
downstream of exon 30 ( ) and those with deletionnp 32
upstream of exon 30 ( ). There was a high percentagenp 11
(66% [21/32]) of red-green defects in the patients with
deletions downstream of exon 30, whereas color defects
were not found in any of the patients with deletions up-
stream of exon 30, except for a patient with deuteranopia
who was previously excluded.
Statistical difference in the Kruskal-Wallis ANOVA test
was found for the CCT Trivector protan ( ,Hp 25.418
), deutan ( , ), and tritan (P ! .001 Hp 31.342 P ! .001 Hp
, ) thresholds (ﬁg. 4) and for the CCT ellip-17.468 P ! .001
ses area ( , ) (ﬁg. 5). These differencesHp 31.765 P ! .001
were between controls and patients with DMD with de-
letions downstream of exon 30 (Tukey post hoc analysis).
No statistical difference was found between the controls
and the patients with DMD with deletions upstream of
exon 30.
A statistically signiﬁcant difference was also found be-
tween controls and patients with DMD with deletions
downstream of exon 30 for the T/P ratio ( ,Hp 11.978
) and for the T/D ratio ( , ). AllPp .003 Fp 11.281 Pp .004
T/P and T/D ratios are shown in table 3.
The improvement of color discrimination with age was
conﬁrmed for both subgroups of patients with DMD with
gene deletion upstream and downstream of exon 30. The
Spearman rank-order correlation data showed reduction
in CCT Trivector thresholds and ellipses area as ages in-
creased (see table 2).
Discussion
Here we report, for the ﬁrst time to our knowledge, that
red-green color vision defect is highly prevalent in pa-
tients with DMD with deletions downstream of exon 30.
Since all but one (11/12) of the patients with deletions
upstream of exon 30 had normal color vision, the present
study suggests that the color defect is related to possible
functional damage associated with Dp260, the dystrophin
isoform located in the outer plexiform layer.6,14–20,22 Pre-
vious studies on evaluation of visual functions in patients
with DMD reported normal ophthalmologic conditions as
well as visual functions, including visual acuity, ocular
motility, and color vision.19,27,44 However, various degrees
of retinal impairment had been found in electrophysiol-
ogical evaluations. The full-ﬁeld ERG of patients with
DMD showed alterations in scotopic and photopic re-
sponses.6,15,16,18,19,22–25,43,45–50 Indications of impairment in
the visual pathways were also observed using visual
evoked potential (VEP) techniques. Benoff et al.47 inves-
tigated the contrast sensitivity mediated by magno- and
parvocellular pathways isolating the responses of the
“ON” and “OFF” subsystems of the visual pathway. They
found impairment in the contrast sensitivity mediated by
the magnocellular-ON pathway in patients with DMD. In
a multimodal evoked potential assessment, Girlanda et
al.50 found reductions for the VEP of patients with DMD
and BMD, but not for other modalities, including soma-
tosensory and auditory evoked potentials.
The lack of agreement between the functional evalua-
tions of vision and the electrophysiological studies re-
ported above might be due to the use of procedures that
were not sufﬁciently sensitive to detect functional im-
pairment. We therefore decided to assess visual function
with sensitive instruments and focused the present study
on color vision.
With the instruments used, wewere able to demonstrate
that color vision impairment in patients with DMD is
highly prevalent. Not only was the incidence of color vi-
sion defect very high, but it was also selective and was
conﬁrmed by two independent and very different tests.
The CCT—a quantitative and sensitive test—showed that
patients with DMD had a red-green defect, and this result
was conﬁrmed by the gold standard used to measure red-
green color defect, the Neitz Anomaloscope. The inci-
dence of color vision defect among the patients withDMD
was 54% (24/44); of these 24 patients, 21 had losses of
the red-green type, whereas only 3, or 7%, had diffuse
color vision loss. This is a much higher proportion than
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Figure 3. Patients with DMD stratiﬁed according to their color vision deﬁciencies, with their region of dystrophin gene deletion
shown. The range of deletion is indicated numerically in the ﬁrst column. For each patient, the length of the DMD gene is shown by
a horizontal black line that represents the extension and location of deletion in this gene. A, All the patients with color vision
impairment. All patients had deletions downstream of exon 30. B, Patients with normal color vision classiﬁcation. The majority have
deletions upstream of exon 30.
expected for congenital protan and deutan defects, which
occur in ∼7%–10% of the male population.40,51
The mechanisms underlying this color vision loss are
not known. Patients with DMD present selective impair-
ment in a function mediated by a speciﬁc neural path-
way—the parvocellular pathway, which mediates red-
green color vision. This pathway is initiated by the re-
sponse of the L and M cones and comprises a neural net-
work from the retina to the lateral geniculate nucleus and,
from there, to several cortical levels. The magnocellular
pathway, whichmediates achromatic functions, is also ini-
tiated by inputs from the L and M cones.52 In the mag-
nocellular pathway, the signals from the L and M cones
are added to convey the information of luminance,
whereas, in the parvocellular pathway, theM and L signals
are compared, and the neural response expresses their dif-
ference, to convey the chromatic information. Chromatic
processing includes, in addition, the blue-yellow pathway
in which the S-cone signals are compared with the added
inputs of the L and M cones.53
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Figure 4. Color discrimination results for the control subjects
and patients with DMD, grouped according the region of the gene
deletion (meanSD) for protan, deutan, and tritan confusion
lines. Statistical difference was found between the controls and
the patients with deletion downstream of exon 30, for all the
confusion lines.
Figure 5. The mean area of the CCT ellipses for controls and for
the patients with DMD stratiﬁed into two groups: those with de-
letion downstream or upstream of exon 30. The area of color dis-
crimination ellipses quantify the ability of the subject to discrim-
inate color in all directions around a point in the chromaticity
diagram. The smaller the area, the better the discrimination. The
downstream group shows statistically signiﬁcant wider ellipses ar-
eas or reduction in color discrimination, compared with the other
two groups.
Our ﬁndings differ from the result of the work of Benoff
et al.,47 who showed that there was magnocellular but not
parvocellular impairment in the VEPs of patients with
DMD. This disagreement could be due to two factors: (1)
The magnocellular pathway is tuned to detect luminance
stimuli as the checkboard stimuli that varied in the size
of the elements and in the contrast level used in that study.
Although the parvocellular pathway also exhibits a re-
sponse to luminance stimuli, the chromatic stimuli, either
red or green, produces the most vigorous activation. (2)
The magnocellular pathway collects the response of many
more cones than the parvocellular pathway. Since the VEP
is a cortical mass response of small amplitude, differences
could be more evident in responses mediated by the mag-
nocellular rather than parvocellular pathway.
In the patients with DMD, we found losses mainly in
the red-green pathway. These losses may originate in the
photoreceptors, since it has been demonstrated by Ueda
et al.12,13 that dystrophin is located within the invagina-
tion of the presynaptic photoreceptor terminal. These in-
vaginated synapses are composed of two lateral processes
from horizontal cells and one central process from the
ON-bipolar cell, which constitutes a synaptic triad con-
tributing to build the ON visual pathway. If the color de-
fect originates in the photoreceptors, there should be a
reduction in all three pathways. In addition to the par-
vocellular pathway, which mediates red-green color vi-
sion, both the magnocellular and koniocellular functions
should be affected, since L and M cones constitute inputs
in these pathways as well as in the parvocellular pathway.
The VEP magnocellular-ON impairment47 and the ERG
ON-pathway impairment6,15 found in patients with DMD
provide functional evidence in favor of this hypothesis.
The vertebrate visual system has a functional separation
of neural pathways that signal ON and OFF responses to
light. The ON cells signal in response to illumination, and
the OFF cells signal when light is turned off. These path-
ways are organized in a concentric center-surround an-
tagonism: an excitatory center and an inhibitory surround
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Table 3. T/P and T/D Trivector
Confusion-Axes Ratios
Study Group T/P T/D
Controls 1.69 (.37) 1.70 (.41)
DMD
Up 30a 1.58 (.20) 1.67 (.28)
Down 30b 1.25 (.31) 1.18 (.28)
NOTE.—Values are given as means (SDs).
a Gene deletion upstream of exon 30.
b Gene deletion downsteam of exon 30.
or vice-versa.54 The main reason for the presence of ON
and OFF channels in the visual system could be to opti-
mize information about increments and decrements of
light to the CNS. The same arrangement occurs in the
processing of chromatic stimuli, in which ON and OFF
signals are generated in response to opponent colors.
Accordingly, the red-green color pathway in the retina
has its bipolar and ganglion cells arranged in two types
of receptive ﬁelds with center-surround spatial antago-
nism of the L and M cones: L-ON versus M-OFF, and L-
OFF versus M-ON.53,55–57 Since the previous literature
shows selective impairment of the ON pathway, it is pos-
sible that the color vision defect that we report could be
reﬂecting the impairment of only the ON-pathway.
The understanding of the S-cone color processing in the
retina is limited, and the existence of the S-OFF cone path-
way in the retina is not established.53,58 The study by Cal-
kins59 shows that the ON bipolar cells make contact with
S cones in two different ways: there are the characteristic
ON-type invaginating contacts and, in addition, other nu-
merous semi-invaginating contacts with the S cones. Since
dystrophin would affect the invaginating contacts because
of its location near the synaptic ribbon, it might not in-
ﬂuence the physiology of these ON bipolars, becausemost
of their contacts with the S cone are located close to but
not directly in the invaginating region. This could explain
why the patients with DMD had normal tritan thresholds.
The present ﬁnding of an association betweenDMDand
red-green color defect in ∼47% of the affected patients
constitutes a new ﬁnding in the area of DMD studies.
The only study that evaluated color vision of the patients
with DMD is that of Sigesmund et al.,27 who conducted a
complete ophthalmologic evaluation including biomi-
croscopy, cycloplegic refraction, fundoscopy, prism and
cover test, ERG, and tests of color vision, stereoacuity, and
visual acuity in 21 patients with a diagnosis of DMD and
5 patients with BMD. Color vision was evaluated in 17 of
21 patients with the use of AO H-R-R, the Ishihara Color
Plates, or the Farnsworth D-15 tests. All patients tested
had normal color vision, except for one with a severe red-
green defect. This patient had a deletion downstream of
exon 30. Since most patients had normal color vision,
extraocular muscle function, stereoacuity, and visual acu-
ity, the authors27 concluded that patients with DMD have
normal vision.
The discrepancy between our data showing a high prev-
alence of red-green color defect in patients with DMD and
the study by Sigesmund et al.27 is probably due to the low
sensitivity of the traditional color tests used in that study.
Indeed, our results of color vision defect in patients with
DMD evaluated with the Ishihara and the AO H-R-R plate
tests are in accordance with the results found by these
authors27 and with the expected proportion for congenital
color defect in the population. The results obtained here
beneﬁtted from a new method for the measurement of
color discrimination, developed in the early 1990s,39
whose norms were provided by Ventura et al.32 This new
procedure has demonstrated a better capacity than the
traditional tests to detect color vision defects in retinal
pathologies like glaucoma and in hypertension,35 Parkin-
son disease,60 nonretinopathic diabetes,31 and mercury in-
toxication,34 as well as in genetic diseases like dominant
optic atrophy61 and Leber’s hereditary optic neuropathy.62
The psychophysical (staircase) method employed and
the four-alternative forced-choice task used by the CCT
made possible a precise quantiﬁcation of the color dis-
crimination threshold. The use of the Neitz Anomalo-
scope, which is the gold standard to identify and classify
red-green color defects, reinforced and conﬁrmed the ex-
istence of the selective red-green color discrimination de-
fect in the patients in this study.
The cluster analysis performed on our data revealed a
strong association between the color thresholds obtained
in the CCT Trivector and the region of gene deletion. Al-
though the full-ﬁeld ERG shows great variability in pa-
tients with DMD, a relationship of these electrophysiol-
ogical losses with the gene-deletion regionwas not veriﬁed
by some authors,19,22 whereas other studies were able to
show a genotype-phenotype correlation6,14,15,20,25 in which
the patients with DMD who had the gene deletion down-
stream of exon 30 had the more preeminent reduction in
the ERG b-wave amplitude. The latter studies, therefore,
strongly suggested that the dystrophin isoform Dp260 is
required for normal retinal function. Our color vision re-
sults are in line with those electrophysiological results,
since the cluster amalgamation shows that color thresh-
olds have a high level of aggregation with the region of
the gene deletion.
The apparent relationship between the region of gene
deletion and color vision defects in patients with DMD
can be seen in ﬁgure 5. This ﬁgure shows the region of
gene deletion in each patient, stratifying them into two
subgroups according to their red-green color vision results:
those with impaired color vision (ﬁg. 5A) and those with
normal color vision (ﬁg. 5B). Red-green color defect was
present in 47% (21/44) of patients with deletion down-
stream of exon 30.
Anomaloscope results from some patients with DMD
that indicated a discrete anomalous trichromacy were not
in agreement with the CCT Trivector thresholds, which
were within the normal limits in the CCT for those pa-
tients. However, their T/P and T/D ratios were lower (∼1.0)
than those of normal subjects (∼1.7). These threshold ra-
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tios might offer an index to be checked before considering
patients’ vision as normal or color defective.
An interesting question is how do these color vision
losses impact the daily life of the patient? We would call
these subclinical symptoms, since they are not material-
ized into complaints. Subjects learn to live with less-than-
perfect, or defective, color vision. Even individuals with
extreme dichromatism often do not ﬁnd out about their
disadvantage until they are adults. A personwhohas never
been faced with another reality has difﬁculties realizing
that she or he is missing information from the world,
unless confronted with speciﬁc tasks that reveal the loss.
This is the basis and motivation of color vision testing—
to create situations in which the chromatic discrimination
can be isolated. Interestingly, our previous experience in
color vision testing in several other pathologies31–34,63–65
showed that very few patients verbalize or are aware of
their difﬁculty to discriminate color or that they have a
deﬁciency.
The improvement of color discrimination with age ob-
served in controls reﬂects the normal development of this
function that reaches its maximum around age 18 years.42
The patients with DMD also showed improvement in
color discrimination measured by the CCT. This ﬁnding
could be interpreted as evidence that the color defect is
nonprogressive in patients with DMD.
Possible cognitive and motor function inﬂuences in the
assessment of visual function were minimized in our re-
sults, since the CCT and Neitz Anomaloscope tasks are
cognitively simple and, in the CCT, button-pressing re-
sponses were not required for patients with severe motor
impairment. We excluded the six patients who had dif-
ﬁculty understanding the CCT instructions. Response re-
liability was measured in the remaining 44 patients by the
assessment of correct responses to a control stimulus that
showed a saturated color. There were no errors, showing
that these patients were paying attention to the stimulus
and were capable of making the discrimination required
in the test.
In conclusion, with the battery of tests that we used,
not only was it possible to identify the existence of losses
in color discrimination, but we were also able to show
that these losses were selective for the red-green axis, an
observation still not understood.
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